Literature DB >> 25787283

A Japanese encephalitis virus genotype 5 molecular clone is highly neuropathogenic in a mouse model: impact of the structural protein region on virulence.

Mélissanne de Wispelaere1, Marie-Pascale Frenkiel1, Philippe Desprès2.   

Abstract

UNLABELLED: Japanese encephalitis virus (JEV) strains can be separated into 5 genotypes (g1 to g5) based on sequence similarity. JEV g5 strains have been rarely isolated and are poorly characterized. We report here the full characterization of a g5 virus generated using a cDNA-based technology and its comparison with a widely studied g3 strain. We did not observe any major differences between those viruses when their infectious cycles were studied in various cell lines in vitro. Interestingly, the JEV g5 strain was highly pathogenic when inoculated to BALB/c mice, which are known to be largely resistant to JEV g3 infection. The study of chimeric viruses between JEV g3 and g5 showed that there was a poor viral clearance of viruses that express JEV g5 structural proteins in BALB/c mice blood, which correlated with viral invasion of the central nervous system and encephalitis. In addition, using an in vitro model of the blood-brain barrier, we were able to show that JEV g5 does not have an enhanced capacity for entering the central nervous system, compared to JEV g3. Overall, in addition to providing a first characterization of the understudied JEV g5, our work highlights the importance of sustaining an early viremia in the development of JEV encephalitis. IMPORTANCE: Genotype 5 viruses are genetically and serologically distinct from other JEV genotypes and can been associated with human encephalitis, which warrants the need for their characterization. In this study, we characterized the in vitro and in vivo properties of a JEV g5 strain and showed that it was more neuropathogenic in a mouse model than a well-characterized JEV g3 strain. The enhanced virulence of JEV g5 was associated with poor viral clearance but not with enhanced crossing of the blood-brain barrier, thus providing new insights into JEV pathogenesis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25787283      PMCID: PMC4442416          DOI: 10.1128/JVI.00358-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Definition of an epitope on Japanese encephalitis virus (JEV) envelope protein recognized by JEV-specific murine CD8+ cytotoxic T lymphocytes.

Authors:  K Takada; H Masaki; E Konishi; M Takahashi; I Kurane
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

2.  Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro.

Authors:  L K Chen; Y L Lin; C L Liao; C G Lin; Y L Huang; C T Yeh; S C Lai; J T Jan; C Chin
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

3.  Japanese encephalitis virus is transported across the cerebral blood vessels by endocytosis in mouse brain.

Authors:  M L Liou; C Y Hsu
Journal:  Cell Tissue Res       Date:  1998-09       Impact factor: 5.249

4.  Accumulation of a 3'-terminal genome fragment in Japanese encephalitis virus-infected mammalian and mosquito cells.

Authors:  Kuo-Chih Lin; Huei-Lan Chang; Ruey-Yi Chang
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Comparison of structural proteins among antigenically different Japanese encephalitis virus strains.

Authors:  H Hasegawa; M Yoshida; S Fujita; Y Kobayashi
Journal:  Vaccine       Date:  1994-07       Impact factor: 3.641

6.  Clinical and immunological risk factors for severe disease in Japanese encephalitis.

Authors:  Daniel H Libraty; Ananda Nisalak; Timothy P Endy; Saroj Suntayakorn; David W Vaughn; Bruce L Innis
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Mar-Apr       Impact factor: 2.184

7.  Strain difference of mouse in susceptibility to Japanese encephalitis virus infection.

Authors:  K Miura; N Goto; H Suzuki; Y Fujisaki
Journal:  Jikken Dobutsu       Date:  1988-10

Review 8.  Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus.

Authors:  Michael S Diamond; Bimmi Shrestha; Erin Mehlhop; Elizabeth Sitati; Michael Engle
Journal:  Viral Immunol       Date:  2003       Impact factor: 2.257

9.  A critical role for induced IgM in the protection against West Nile virus infection.

Authors:  Michael S Diamond; Elizabeth M Sitati; Lindzy D Friend; Stephen Higgs; Bimmi Shrestha; Michael Engle
Journal:  J Exp Med       Date:  2003-12-08       Impact factor: 14.307

Review 10.  Transmission cycles, host range, evolution and emergence of arboviral disease.

Authors:  Scott C Weaver; Alan D T Barrett
Journal:  Nat Rev Microbiol       Date:  2004-10       Impact factor: 60.633

View more
  13 in total

1.  Degradation of MicroRNA miR-466d-3p by Japanese Encephalitis Virus NS3 Facilitates Viral Replication and Interleukin-1β Expression.

Authors:  Hui Jiang; Lige Bai; Lina Ji; Zhuofang Bai; Jianwei Su; Tian Qin; Guojun Wang; Vinod Balasubramaniam; Xiao Wang; Min Cui; Jing Ye; Shengbo Cao; Guangpeng Li; Yang Yang
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

2.  A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts.

Authors:  Mélissanne de Wispelaere; Cécile Khou; Marie-Pascale Frenkiel; Philippe Desprès; Nathalie Pardigon
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

3.  A Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles Elicits Broad Neutralizing Antibody Response in Pigs.

Authors:  Mélissanne de Wispelaere; Meret Ricklin; Philippe Souque; Marie-Pascale Frenkiel; Sylvie Paulous; Obdulio Garcìa-Nicolàs; Artur Summerfield; Pierre Charneau; Philippe Desprès
Journal:  PLoS Negl Trop Dis       Date:  2015-10-05

4.  European Aedes albopictus and Culex pipiens Are Competent Vectors for Japanese Encephalitis Virus.

Authors:  Mélissanne de Wispelaere; Philippe Desprès; Valérie Choumet
Journal:  PLoS Negl Trop Dis       Date:  2017-01-13

5.  Development of a model of Saint Louis encephalitis infection and disease in mice.

Authors:  Rafael Elias Marques; Juliana L Del Sarto; Rebeca P F Rocha; Giovanni F Gomes; Allysson Cramer; Milene A Rachid; Danielle G Souza; Maurício L Nogueira; Mauro M Teixeira
Journal:  J Neuroinflammation       Date:  2017-03-22       Impact factor: 8.322

6.  Amino Acid at Position 166 of NS2A in Japanese Encephalitis Virus (JEV) is Associated with In Vitro Growth Characteristics of JEV.

Authors:  Shigeru Tajima; Satoshi Taniguchi; Eri Nakayama; Takahiro Maeki; Takuya Inagaki; Chang-Kweng Lim; Masayuki Saijo
Journal:  Viruses       Date:  2020-06-30       Impact factor: 5.048

7.  Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.

Authors:  Lei Cao; Shihong Fu; Xiaoyan Gao; Minghua Li; Shiheng Cui; Xiaolong Li; Yuxi Cao; Wenwen Lei; Zhi Lu; Ying He; Huanyu Wang; Jinghua Yan; George Fu Gao; Guodong Liang
Journal:  PLoS Negl Trop Dis       Date:  2016-05-03

8.  Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody.

Authors:  Nimesh Gupta; Mélissanne de Wispelaere; Maxime Lecerf; Manjula Kalia; Tobias Scheel; Sudhanshu Vrati; Claudia Berek; Srinivas V Kaveri; Philippe Desprès; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  Sci Rep       Date:  2015-11-06       Impact factor: 4.379

Review 9.  Reverse Genetic Approaches for the Generation of Recombinant Zika Virus.

Authors:  Ginés Ávila-Pérez; Aitor Nogales; Verónica Martín; Fernando Almazán; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2018-10-31       Impact factor: 5.048

10.  Effects of the Japanese Encephalitis Virus Genotype V-Derived Sub-Viral Particles on the Immunogenicity of the Vaccine Characterized by a Novel Virus-Like Particle-Based Assay.

Authors:  Sarah Honjo; Michiaki Masuda; Tomohiro Ishikawa
Journal:  Vaccines (Basel)       Date:  2019-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.